Abstract 331P
Background
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has killed over five hundred thousand people and has infected over 13 million people across the world in over 200 countries. Cancer patients fall under the high-risk category and are susceptible to the SARS-CoV-2 infection given the need for frequent hospital visits.
Methods
In this study, I analysed data from 46 cancer patients who were affected with different types of cancers (Table) and continued to receive cytotoxic treatment between January 2020 till July 2020. Table: 331P
Summary of the types of cancer and the treatment regimen of the 46 patients
Type of cancer | Number of patients | Treatment regimen |
Astrocytoma | 1 | Temodal + Bevacizumab |
Breast | 3 | EC + T |
Breast | 8 | EC + TC |
Breast | 4 | EC + THP |
Colorectal cancer | 4 | FOLFOX |
Colorectal cancer | 3 | FOLFIRI |
Colorectal cancer | 1 | FOLFOX + Bevacizumab |
Ewing sarcoma | 1 | VCD/IE |
Gastric cancer | 4 | FLOT |
Gastric cancer | 2 | XELOX |
Lung cancer | 4 | Docetaxel + Carboplatin |
Lung cancer | 1 | Topotecan |
Lung cancer | 4 | Etoposide + Carboplatin |
Lung cancer | 1 | Docetaxel + Cisplatin |
Osteosarcoma | 1 | OS99 |
Osteosarcoma | 1 | HD-MTX |
Pancreatic cancer | 2 | FOLFIRINOX |
Small bowel | 1 | FOLFOX |
Results
All the 46 patients included in the study completed their cytotoxic regimen without developing SARS-CoV-2 infection between January till July 2020.
Conclusions
The results from the study led to the hypothesis that three factors which were common among the cancer patients included in the study namely, 1) the use of granulocyte colony-stimulating factor (G-CSF), 2) the use of dexamethasone and, 3) dysbiosis of microbiome among cancer patients might be potential reasons for evading the deadly SARS-CoV-2 infection, despite their compromised immune status and a high likelihood of repeated exposure during hospital visits in comparison to the healthy general population, who are less likely to visit hospitals during the pandemic. The study aims to provide an alternate perspective and instigate discussion over the continuation of providing cancer care amidst the pandemic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session